Resultados: 5

J. bras. econ. saúde (Impr.); 15 (1), 2023

Objective: The study aimed to describe the profile and economic burden of patients with depression from the perspective of the Brazilian Private Healthcare System (PHS). Methods: A two-step methodological quantitative-qualitative research design was performed: retrospective descriptive analysis of the Or...

Texto completo

J. bras. econ. saúde (Impr.); 15 (1), 2023

This study describes the healthcare resource use and costs associated with anxiety assessing claim database outcomes and expert opinion from the perspective of the Brazilian Private Healthcare System. A retrospective analysis of the Orizon database was conducted, containing claims data of anxiety patient...

Texto completo

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: In the private healthcare sector in Brazil, the dearth of information regarding transfusion cost may compromise the management of conditions requiring long-term transfusion. Therefore, the present study aimed to estimate the cost of chronic red blood cell (RBC) transfusion in this context. Met...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 11 (3), 2019

Objective: To reflect about current pain management in cancer patients treated under the Brazilian Private Healthcare System, considering legal boundaries, access to essential drugs and involved ethical issues. Panelists aimed to reach a consensus about recommendations to increase access to proper analge...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 10 (2), 2018

Background: Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia. Lipegfilgrastim is a long-acting, once-per-cycle G-CSF, while Brazil’s standard of care is short-acting filgrastim. A cost-effectiveness and budget impact analysis of lipegfilgrastim was con...

Texto completo (link principal)     Texto completo (link alternativo)